The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society

@article{Howe2017TheSM,
  title={The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society},
  author={J. Howe and K. Cardona and D. Fraker and E. Kebebew and B. Untch and Yi-Zarn Wang and C. Law and E. Liu and M. Kim and Y. Menda and Brian G Morse and E. Bergsland and J. Strosberg and E. Nakakura and R. Pommier},
  journal={Pancreas},
  year={2017},
  volume={46},
  pages={715–731}
}
Abstract Small bowel neuroendocrine tumors (SBNETs) have been increasing in frequency over the past decades, and are now the most common type of small bowel tumor. Consequently, general surgeons and surgical oncologists are seeing more patients with SBNETs in their practices than ever before. The management of these patients is often complex, owing to their secretion of hormones, frequent presentation with advanced disease, and difficulties with making the diagnosis of SBNETs. Despite these… Expand
Surgical Principles in the Management of Small Bowel Neuroendocrine Tumors
TLDR
Patients with metastatic SB NETs (localized or metastatic) to be managed at experienced centers by a multidisciplinary team to improve patients’ symptoms and long-term survival. Expand
Management of Small Bowel Neuroendocrine Tumors
TLDR
Ccinoid syndrome, which is mostly managed by somatostatin analogue therapy and the serotonin antagonist telotristat etiprate for refractory diarrhea, as well as neuroendocrine carcinoma will be reviewed. Expand
Surgery and Perioperative Management in Small Intestinal Neuroendocrine Tumors
TLDR
The aim of this paper is to review the surgical indications and techniques, and perioperative and postoperative management of SI-NETs. Expand
The Landmark Series: Management of Small Bowel Neuroendocrine Tumors
TLDR
Important studies influencing the management of small bowel neuroendocrine tumors are discussed and the limitations of current evidence regarding surgical interventions for SBNETs are discussed. Expand
Minimally Invasive Surgery for Ileal Neuroendocrine Tumors
TLDR
The largest series of MIS for i-NETs was reported and it was shown the goals of surgery for this disease can be achieved, however, the short-term outcomes of MIS remain ill-defined. Expand
Management of Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEPNETs): A Review.
TLDR
A review of NETs and focused on management of well-differentiated gastroenteropancreatic neuroendocrine tumors (GEPNETs) and carcinoid syndrome, finding slow-growing tumors that remain asymptomatic for a long duration and can be either nonfunctioning or functioning. Expand
Evaluating Nationwide Application of Minimally Invasive Surgery for Treatment of Small Bowel Neuroendocrine Neoplasms
TLDR
Laroscopic resection was the approach in 29% of SB-NEN at a national level with selection of the more favorable patients and remained independently associated with better overall survival, but residual confounding cannot be excluded. Expand
The small neuroendocrine intestine tumor as the cause of acute gastrointestinal obstruction and diffuse peritonitis – case report
NET is a group of mostly malignant neoplasms with neuroendocrine differentiation. NET tumors are usually located in the small bowel (sbNET), in most cases their symptoms are the non-specific andExpand
The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors
TLDR
The panel reviewed a series of questions regarding the medical management of patients with pancreatic neuroendocrine tumors as well as questions regarding surveillance after resection and recommended recommendations which were circulated to all panel members for a final approval. Expand
Comparative safety review of the current therapies for gastroenteropancreatic neuroendocrine tumors
TLDR
The only true curative option for NENs remains surgery, whereas high-grade advanced neuroendocrine carcinomas should be primarily managed with platinum-based chemotherapy. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 136 REFERENCES
Surgical Treatment of NEN of Small Bowel: A Retrospective Analysis
TLDR
Mesenteric lymph node metastases are almost invariably present and have significant impact on patients’ prognosis and early surgical treatment should be the goal in order to prevent complications. Expand
Consensus guidelines for the management and treatment of neuroendocrine tumors.
TLDR
A set of consensus tables intended to complement the North American Neuroendocrine Tumor Society guidelines and serve as a quick, accessible reference for the practicing physician are presented. Expand
The management of extrapulmonary poorly differentiated (high-grade) neuroendocrine carcinomas.
TLDR
Chemoradiation should be considered when primary resection would lead to significant morbidity, such as with rectal, pancreas, and esophageal HGNECs, and a multimodality approach with either neoadjuvant or adjuvant therapy is warranted. Expand
The NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors: Well-Differentiated Neuroendocrine Tumors of the Jejunum, Ileum, Appendix, and Cecum
TLDR
Well-differentiated neuroendocrine tumors (NETs) of the jejunum, ileum, and appendix are also collectively known as midgut carcinoids and have substantial risk of relapse after resection and need to be followed for at least 7 years. Expand
Surgery for small-bowel neuroendocrine tumors: Is there any benefit of the laparoscopic approach?
TLDR
Overall survival and PFS did not show any difference when comparing the laparoscopic and open groups, and in selected patients, laparoscopy for SBNE tumors is feasible and associated with a shorter hospital stay than laparotomy. Expand
The Value of Preoperative Imaging in Small Bowel Neuroendocrine Tumors
TLDR
CT and SRS are complementary in making the diagnosis of SBNET, with CT giving more precise anatomical detail, while SRS helps to confirm that lesions are NETs and is useful for identifying occult extrahepatic sites of metastatic disease. Expand
Liver-directed surgery of neuroendocrine metastases: What is the optimal strategy?
TLDR
Lowering the debulking target threshold to 70% may benefit NET patients by increasing eligibility for cytoreduction, which is associated with improved survival. Expand
Hepatic neuroendocrine metastases: does intervention alter outcomes?
TLDR
Hepatic metastases from neuroendocrine tumors are best managed with a multidisciplinary approach, and both HAE and surgical resection provide excellent palliation of hormonal and pain symptoms. Expand
Surgical Management of Hepatic Neuroendocrine Tumor Metastasis: Results from an International Multi-Institutional Analysis
TLDR
Liver-directed surgery for NELM is associated with prolonged survival; however, the majority of patients will develop recurrent disease. Expand
Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival.
TLDR
Hematic resection for metastatic neuroendocrine tumors is safe and achieves symptom control in most patients, and is justified by its effects on survival and quality of life. Expand
...
1
2
3
4
5
...